Regenxbio Q2 EPS $(1.38) Misses $(1.10) Estimate, Sales $21.36M Miss $28.11M Estimate

Author: Benzinga Newsdesk | August 07, 2025 07:06am
Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(1.10) by 25.8 percent. This is a 31.43 percent decrease over losses of $(1.05) per share from the same period last year. The company reported quarterly sales of $21.36 million which missed the analyst consensus estimate of $28.11 million by 24.02 percent. This is a 4.20 percent decrease over sales of $22.30 million the same period last year.

Posted In: RGNX